June 24 (Reuters) - Sangamo Therapeutics Inc SGMO.O:
SANGAMO THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM REGISTRATIONAL STAAR STUDY IN FABRY DISEASE
SANGAMO THERAPEUTICS INC - ISARALGAGENE CIVAPARVOVEC SHOWS FAVORABLE SAFETY AND TOLERABILITY PROFILE
SANGAMO THERAPEUTICS INC - TO SUBMIT BLA IN 2026
SANGAMO THERAPEUTICS INC - STAAR STUDY SHOWS POSITIVE MEAN ANNUALIZED EGFR SLOPE AT 52 WEEKS
Source text: ID:nBwbmFVVVa
Further company coverage: SGMO.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.